Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942

BACKGROUND: Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-powder formulation containing CDP7766, a high-affi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgess, Gary, Boyce, Malcolm, Jones, Margaret, Larsson, Lars, Main, Mark J., Morgan, Frazer, Phillips, Peter, Scrimgeour, Alison, Strimenopoulou, Foteini, Vajjah, Pavan, Zamacona, Miren, Palframan, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156733/
https://www.ncbi.nlm.nih.gov/pubmed/30146344
http://dx.doi.org/10.1016/j.ebiom.2018.07.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156733/
https://www.ncbi.nlm.nih.gov/pubmed/30146344
http://dx.doi.org/10.1016/j.ebiom.2018.07.035

Ejemplares similares